{"id":"W4388487685","doi":"10.1158/1078-0432.ccr-23-2249","title":"Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Clinical endpoint; Cohort; Bevacizumab; Internal medicine; Oncology; Durvalumab; PARP inhibitor; Adverse effect; Cancer; Clinical trial; Chemotherapy; Nivolumab; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005251127,0.000635082,0.001968741,0.0008179876,0.0006482223,0.00009215024,0.0003658805,0.0004613817,0.001248264],"category_scores_gemma":[0.001113576,0.000457449,0.0002668944,0.003281053,0.001037974,0.000221224,0.000297402,0.00225314,0.0003326031],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.004508598,"about_ca_system_score_gemma":0.007298252,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02185708,"about_ca_topic_score_gemma":0.028001,"domain_scores_codex":[0.9904517,0.001758005,0.001748311,0.002022567,0.002412559,0.001606842],"domain_scores_gemma":[0.9945065,0.00181538,0.0003319439,0.001365233,0.001068121,0.0009127877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1403453,0.01542323,0.7681303,0.0001752981,0.002226975,0.006257548,0.01526685,0.0003791045,0.001088995,0.00003565286,0.006846633,0.04382408],"study_design_scores_gemma":[0.4194598,0.09432239,0.4267974,0.003399825,0.0007806589,0.0001602898,0.01696054,0.009540199,0.008329791,0.0001115605,0.01835691,0.001780575],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843839,0.0003142142,0.00001487954,0.003497386,0.0008478394,0.009322258,0.0002377573,0.0003232819,0.001058417],"genre_scores_gemma":[0.9705458,0.002444026,0.0002242689,0.0005159792,0.001340589,0.009153813,0.0001108642,0.0001875581,0.01547713],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3413329,"threshold_uncertainty_score":0.9997877,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.317749283599929,"score_gpt":0.5762641648363642,"score_spread":0.2585148812364352,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}